Corient Private Wealth LLC Sells 14,659 Shares of Moderna, Inc. (NASDAQ:MRNA)

Corient Private Wealth LLC decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 44.2% in the fourth quarter, Holdings Channel reports. The firm owned 18,538 shares of the company’s stock after selling 14,659 shares during the quarter. Corient Private Wealth LLC’s holdings in Moderna were worth $771,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc acquired a new stake in shares of Moderna in the 4th quarter valued at $37,000. Venturi Wealth Management LLC grew its holdings in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after purchasing an additional 388 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on MRNA shares. Bank of America dropped their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Morgan Stanley reduced their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Finally, UBS Group lowered their target price on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $59.00.

Moderna Trading Up 2.0 %

Shares of MRNA opened at $32.12 on Friday. The stock has a market capitalization of $12.42 billion, a price-to-earnings ratio of -3.46 and a beta of 1.86. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The firm has a fifty day simple moving average of $34.78 and a 200 day simple moving average of $44.93.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.